Holstein v. Collins

Plain English (For Everyone)

Imagine a doctor has a great idea for treating a disease, like figuring out which patients would benefit most from a certain medicine. This court said that simply having this idea, or a general method for identifying those patients and giving them the treatment, isn't something you can get a patent for. It's like trying to patent the idea of 'using a recipe' – the idea itself is too basic, and you need more specific, inventive steps to get a patent.

For Legal Practitioners

The Federal Circuit affirmed PTAB's § 101 rejection of method-of-treatment claims, finding them directed to the abstract idea of 'identifying a patient population and administering a treatment based on that identification.' Crucially, the court held that the claims lacked an inventive concept sufficient to transform the abstract idea into patent-eligible subject matter. Practitioners should note the court's focus on whether the claims merely recite a fundamental concept or add a specific, inventive application, impacting strategy for drafting and prosecuting method claims, particularly in diagnostic and therapeutic fields.

For Law Students

This case tests patent eligibility under 35 U.S.C. § 101, specifically concerning abstract ideas in the context of medical treatments. The court found the claims directed to the abstract idea of identifying and treating a patient population, a fundamental concept. This aligns with the Alice/Mayo framework, where claims must contain an 'inventive concept' beyond the abstract idea itself to be patent-eligible. Exam issue: Does the claimed method add enough specific, inventive steps to avoid being merely an abstract idea, or is it a general diagnostic/treatment concept?

Newsroom Summary

The Federal Circuit ruled that a patent for a method of treating a condition was invalid because it claimed an abstract idea. The court found the patent's core idea – identifying a patient group and giving them treatment – was too general to be patented, impacting companies seeking to patent medical treatment methods.

Constitutional Issues

Patentability of an invention under 35 U.S.C. § 103 (Obviousness)

Rule Statements

A patent may not be obtained if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.

To determine obviousness, the court considers the scope and content of the prior art, the differences between the prior art and the claims at issue, the level of ordinary skill in the pertinent art, and secondary considerations.

Scenario: You've developed a new way to identify patients who will respond best to a specific cancer drug and have a clear protocol for administering it. You want to patent this method.

Your Rights: You have the right to seek a patent, but this ruling suggests that if your method is essentially just the abstract idea of identifying a patient group and administering treatment based on that identification, without significant inventive steps beyond that general concept, your patent application may be rejected under 35 U.S.C. § 101.

What To Do: When seeking a patent for a method of treatment, ensure your claims detail specific, inventive steps that go beyond the mere identification of a patient population and the general administration of a treatment. Consult with a patent attorney to draft claims that add an 'inventive concept' sufficient to distinguish your invention from an abstract idea.

Is it legal to patent a method for identifying a specific group of patients and then administering a treatment to them?

It depends. If the method is merely the abstract idea of identifying a patient population and administering a treatment based on that identification, it is likely not patent-eligible. However, if the method includes significant, specific, and inventive steps beyond this general concept, it may be patent-eligible.

This ruling applies to patent eligibility in the United States, as interpreted by the Federal Circuit.

For Biotechnology and Pharmaceutical Companies

Companies seeking to patent diagnostic or therapeutic methods may face increased scrutiny under § 101. Claims must be carefully drafted to include specific, inventive steps that transform the abstract idea into a patent-eligible application, rather than claiming the general concept of patient identification and treatment.

For Patent Attorneys and Agents

This decision reinforces the importance of the Alice/Mayo framework for method claims, particularly in life sciences. Attorneys must focus on demonstrating an 'inventive concept' in claim drafting and prosecution to overcome § 101 rejections, emphasizing specific technical innovations rather than broad diagnostic or treatment strategies.

Q: What is Holstein v. Collins about?

Holstein v. Collins is a case decided by Federal Circuit on January 30, 2026.

Q: What court decided Holstein v. Collins?

Holstein v. Collins was decided by the Federal Circuit, which is part of the federal judiciary. This is a federal appellate court.

Q: When was Holstein v. Collins decided?

Holstein v. Collins was decided on January 30, 2026.

Q: What is the citation for Holstein v. Collins?

The citation for Holstein v. Collins is . Use this citation to reference the case in legal documents and research.

Q: What is the full case name and citation for the Holstein v. Collins decision?

The full case name is Holstein v. Collins, and it was decided by the United States Court of Appeals for the Federal Circuit (CAFC). While a specific citation number is not provided in the summary, it is a decision from the CAFC concerning patent eligibility.

Q: Who were the parties involved in the Holstein v. Collins case?

The parties involved were the patent holder, identified as Holstein, and the party challenging the patent's validity, identified as Collins. The case also involved the Patent Trial and Appeal Board (PTAB), whose decision was under review.

Q: What was the subject matter of the patent in Holstein v. Collins?

The patent in question claimed a "method of treating" a specific medical condition. The core of the dispute centered on whether this method was eligible for patent protection under U.S. law.

Q: Which court decided the Holstein v. Collins case?

The United States Court of Appeals for the Federal Circuit (CAFC) decided the Holstein v. Collins case. This court has exclusive jurisdiction over appeals from decisions of the U.S. district courts in patent infringement suits and appeals from the Patent Trial and Appeal Board (PTAB).

Q: When was the Holstein v. Collins decision issued?

The provided summary does not specify the exact date the Holstein v. Collins decision was issued. However, it is a recent decision from the Federal Circuit affirming a PTAB ruling.

Q: Is Holstein v. Collins published?

Holstein v. Collins is a published, precedential opinion. Published opinions carry precedential weight and can be cited as authority in future cases.

Q: What was the ruling in Holstein v. Collins?

The court ruled in favor of the defendant in Holstein v. Collins. Key holdings: The court held that claims directed to a method of treating a condition were not patent-eligible under 35 U.S.C. § 101 because they claimed the abstract idea of identifying a patient population and administering treatment based on that identification.; The court reasoned that this abstract idea is a fundamental concept that cannot be monopolized by a patent.; The court found that the claims did not add an "inventive concept" sufficient to transform the abstract idea into a patent-eligible application, as the steps described were routine and conventional.; The court applied the two-step Alice/Mayo framework to determine patent eligibility, first identifying the abstract idea and then determining if the claims amounted to significantly more than the abstract idea.; The court rejected the patentee's argument that the claims were directed to a specific diagnostic and treatment protocol, finding that the claims were framed broadly and encompassed the abstract idea itself..

Q: Why is Holstein v. Collins important?

Holstein v. Collins has an impact score of 60/100, indicating significant legal impact. This decision further clarifies the application of the Alice/Mayo framework to method-of-treatment claims, emphasizing that claims directed to abstract ideas, even in the medical field, must include an inventive concept beyond routine identification and treatment steps. It signals continued scrutiny of patents that claim fundamental concepts without significant inventive application, impacting innovation in personalized medicine and diagnostics.

Q: What precedent does Holstein v. Collins set?

Holstein v. Collins established the following key holdings: (1) The court held that claims directed to a method of treating a condition were not patent-eligible under 35 U.S.C. § 101 because they claimed the abstract idea of identifying a patient population and administering treatment based on that identification. (2) The court reasoned that this abstract idea is a fundamental concept that cannot be monopolized by a patent. (3) The court found that the claims did not add an "inventive concept" sufficient to transform the abstract idea into a patent-eligible application, as the steps described were routine and conventional. (4) The court applied the two-step Alice/Mayo framework to determine patent eligibility, first identifying the abstract idea and then determining if the claims amounted to significantly more than the abstract idea. (5) The court rejected the patentee's argument that the claims were directed to a specific diagnostic and treatment protocol, finding that the claims were framed broadly and encompassed the abstract idea itself.

Q: What are the key holdings in Holstein v. Collins?

1. The court held that claims directed to a method of treating a condition were not patent-eligible under 35 U.S.C. § 101 because they claimed the abstract idea of identifying a patient population and administering treatment based on that identification. 2. The court reasoned that this abstract idea is a fundamental concept that cannot be monopolized by a patent. 3. The court found that the claims did not add an "inventive concept" sufficient to transform the abstract idea into a patent-eligible application, as the steps described were routine and conventional. 4. The court applied the two-step Alice/Mayo framework to determine patent eligibility, first identifying the abstract idea and then determining if the claims amounted to significantly more than the abstract idea. 5. The court rejected the patentee's argument that the claims were directed to a specific diagnostic and treatment protocol, finding that the claims were framed broadly and encompassed the abstract idea itself.

Q: What cases are related to Holstein v. Collins?

Precedent cases cited or related to Holstein v. Collins: Alice Corp. v. CLS Bank Int'l, 573 U.S. 208 (2014); Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012).

Q: What was the primary legal issue in Holstein v. Collins?

The primary legal issue was whether the claims of the patent for a "method of treating" a condition were patent-eligible under 35 U.S.C. § 101, which governs subject matter eligibility for patents.

Q: What did the Federal Circuit hold regarding the patent claims in Holstein v. Collins?

The Federal Circuit affirmed the PTAB's decision, holding that the patent claims were not patent-eligible under 35 U.S.C. § 101. The court found the claims were directed to an abstract idea.

Q: Why did the court in Holstein v. Collins find the patent claims to be an abstract idea?

The court reasoned that the claims were directed to the abstract idea of "identifying a patient population and administering a treatment based on that identification." This was considered a fundamental concept that cannot be monopolized by a patent.

Q: What is the legal standard for patent eligibility under 35 U.S.C. § 101 as applied in Holstein v. Collins?

The court applied the two-step Alice/Mayo framework. First, it determined if the claims were directed to a patent-ineligible concept, such as an abstract idea. Second, if so, it assessed whether the claims provided an "inventive concept" sufficient to transform the abstract idea into a patent-eligible application.

Q: Did the patent claims in Holstein v. Collins add an 'inventive concept' according to the court?

No, the court found that the claims did not add enough inventive concept to transform the abstract idea into a patent-eligible application. The steps described in the claims were considered routine and conventional in the field.

Q: What does it mean for a patent claim to be 'directed to an abstract idea'?

A claim is 'directed to an abstract idea' if it essentially seeks to patent a fundamental concept or a law of nature, mathematical formula, or natural phenomenon, rather than a specific, practical application of that concept. In this case, identifying patient groups and treating them was deemed abstract.

Q: What is the significance of the 'identifying a patient population and administering a treatment based on that identification' concept in this case?

This concept was central to the court's determination that the claims were directed to an abstract idea. The court viewed this as a fundamental mental process or a general diagnostic and treatment strategy that is not patentable in itself.

Q: What is 35 U.S.C. § 101 and why is it important in this case?

35 U.S.C. § 101 defines what subject matter is eligible for patent protection in the United States, stating that 'Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor.' The Holstein court interpreted this statute to exclude abstract ideas without sufficient inventive application.

Q: How does Holstein v. Collins affect me?

This decision further clarifies the application of the Alice/Mayo framework to method-of-treatment claims, emphasizing that claims directed to abstract ideas, even in the medical field, must include an inventive concept beyond routine identification and treatment steps. It signals continued scrutiny of patents that claim fundamental concepts without significant inventive application, impacting innovation in personalized medicine and diagnostics. As a decision from a federal appellate court, its reach is national. This case is moderate in legal complexity to understand.

Q: How does the Holstein v. Collins decision impact patents for medical methods?

The decision reinforces that methods of treatment, particularly those involving identifying patient groups and applying treatments based on that identification, may be challenged as abstract ideas under § 101. Patent applicants must demonstrate an inventive concept beyond the mere abstract idea.

Q: Who is most affected by the ruling in Holstein v. Collins?

The ruling primarily affects patent holders and applicants seeking patents for diagnostic or therapeutic methods, especially those involving personalized medicine or treatment algorithms. It also impacts companies that might be accused of infringing such patents.

Q: What should inventors do to ensure their medical method patents are eligible after Holstein v. Collins?

Inventors should focus on claims that integrate specific, unconventional technical steps or elements that transform the abstract idea into a concrete and practical application. Simply describing a diagnostic or treatment strategy is insufficient; the claims must add something more inventive.

Q: Could this ruling affect existing patents for medical treatments?

Yes, existing patents for medical treatments that are similar in scope to the claims in Holstein v. Collins could be vulnerable to challenges based on patent eligibility under § 101. Such challenges would likely occur during litigation or reexamination proceedings.

Q: What are the potential compliance implications for healthcare providers or companies based on this decision?

While primarily a patent law case, the ruling could indirectly affect healthcare providers if it leads to the invalidation of patents covering specific treatment protocols they utilize. This might reduce licensing fees or open up previously patented methods for broader use.

Q: How does the Holstein v. Collins decision fit into the broader history of patent eligibility challenges for diagnostic and treatment methods?

This case continues a trend of increased scrutiny on patent eligibility for diagnostic and treatment methods, following landmark Supreme Court decisions like Mayo Collaborative Services v. Prometheus Laboratories, Inc. and Association for Molecular Pathology v. Myriad Genetics, Inc., which also found certain methods and genes unpatentable.

Q: What legal precedent did the court likely consider in Holstein v. Collins?

The court undoubtedly considered Supreme Court precedent on patent eligibility, particularly Mayo Collaborative Services v. Prometheus Laboratories, Inc., which established a framework for analyzing claims directed to laws of nature and abstract ideas, and the Federal Circuit's own application of this framework in subsequent cases.

Q: How does the Holstein v. Collins ruling compare to other recent Federal Circuit decisions on § 101?

The ruling aligns with recent Federal Circuit jurisprudence that has often found diagnostic and treatment method claims ineligible under § 101 when they are perceived as claiming abstract ideas or natural phenomena without sufficient inventive application, emphasizing the need for a concrete, inventive step.

Q: What was the docket number in Holstein v. Collins?

The docket number for Holstein v. Collins is 23-1451. This identifier is used to track the case through the court system.

Q: Can Holstein v. Collins be appealed?

Potentially — decisions from federal appellate courts can be appealed to the Supreme Court of the United States via a petition for certiorari, though the Court accepts very few cases.

Q: How did the Holstein v. Collins case reach the Federal Circuit?

The case reached the Federal Circuit on appeal from a decision by the Patent Trial and Appeal Board (PTAB). The PTAB had determined that the patent claims were not eligible for patenting under 35 U.S.C. § 101, and the patent holder appealed this decision to the CAFC.

Q: What was the specific procedural posture of the PTAB's decision being reviewed?

The PTAB had issued a final written decision finding the challenged patent claims invalid for failing to meet the patent eligibility requirements of 35 U.S.C. § 101. The Federal Circuit's review was of this PTAB decision.

Q: What is the role of the Patent Trial and Appeal Board (PTAB) in cases like Holstein v. Collins?

The PTAB is an administrative tribunal within the U.S. Patent and Trademark Office that hears appeals from final rejections of patent applications and reviews decisions in inter partes reviews and post-grant reviews. In this case, the PTAB made the initial determination of patent ineligibility that was appealed.

Q: What happens after the Federal Circuit's decision in Holstein v. Collins?

The Federal Circuit affirmed the PTAB's decision, meaning the patent claims at issue were found ineligible for patent protection. The case could potentially be appealed to the Supreme Court, but absent that, the PTAB's ruling stands as affirmed.